<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131531</url>
  </required_header>
  <id_info>
    <org_study_id>BLCR</org_study_id>
    <nct_id>NCT03131531</nct_id>
  </id_info>
  <brief_title>Bergamo Lymphoid Cancer Registry</brief_title>
  <official_title>Bergamo Lymphoid Cancer Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry has been established to gain a better understanding of the clinical and
      biological characteristics and outcome of patients with lymphoid cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma,
      represents the most common hematologic malignancy. Despite the overall prognosis improved in
      the last 10 years, there are many open issues that need to be addressed, specifically
      refractoriness to standard treatment, disease recurrence and outcome with new drug in the so
      called &quot;real world&quot; setting. Since the Hematology and Bone Marrow Transplant Unit at
      &quot;Ospedale Papa Giovanni XIII&quot; of Bergamo has developed specific tools to collect clinical
      data thought fully validated electronic charts and biological specimens thanks to a
      regulatory compliant biobanking program, the aim of this study is to collect clinical and
      biological information of lymphoid cancer patients. The cohort of patients enrolled will
      permit to analyze the practice pattern, perform biological correlative studies of great
      translational potential with relevance to clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">March 23, 2037</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>20 years</time_frame>
    <description>Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>20 years</time_frame>
    <description>Analyzed only for patients in complete response, as time from achievement of the complete response to relapse or death due to disease or acute toxicity of treatment, stratified according to intervention and baseline characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>20 years</time_frame>
    <description>Analyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to intervention and baseline characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative studies</measure>
    <time_frame>20 years</time_frame>
    <description>Association between clinical and biologic characteristics</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Hodgkin lymphoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Hodgkin lymphoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient registry</intervention_name>
    <description>Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures</description>
    <arm_group_label>Hodgkin lymphoma</arm_group_label>
    <arm_group_label>Non-Hodgkin lymphoma</arm_group_label>
    <arm_group_label>Myeloma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological specimens include peripheral blood, serum, plasma, bone marrow, lymph node, normal
      or disease-infiltrated tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for this study are patients with a diagnosis of lymphoid cancer in charge
        of the Hematology and Bone Marrow Transplant Unit &quot;Ospedale Papa Giovanni XIII&quot; of Bergamo.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years or older

          -  Written informed consent

          -  Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

        Exclusion Criteria:

        - Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Rambaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Rambaldi, MD</last_name>
    <phone>+39.035.2673683</phone>
    <email>arambaldi@asst-pg23.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Gritti, MD, PhD</last_name>
    <phone>+39.035.2673679</phone>
    <email>g.gritti@asst-pg23.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Gritti, MD, PhD</last_name>
      <phone>+39.035.2673684</phone>
      <email>g.gritti@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Gritti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>Rambaldi Alessandro</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

